Search - tctmd.com

Displaying 1 - 20 of 55

Sort: Relevancy | Date

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Michael O'Riordan

September 13, 2016

News Daily News

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

Todd Neale

August 04, 2016

News Daily News

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

L.A. McKeown

July 28, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Caitlin E. Cox

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

L.A. McKeown

May 26, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Industry News

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

March 06, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Daily News

Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns

Todd Neale

January 18, 2016

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Industry News

New Publication Featuring GlycoMark® Test Highlights Association of Hyperglycemic Excursions With Cardiovascular Outcomes And Mortality

November 17, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

Advertisement

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Study Shows Surprising Range of Risk After Acute MI Among Patients With Diabetes

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

New Publication Featuring GlycoMark® Test Highlights Association of Hyperglycemic Excursions With Cardiovascular Outcomes And Mortality

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content